Pierre‐Marie Girard

Author

Pierre‐Marie Girard

Also Known As

ANRS 140 DREAM Study Group, Candice Estellat, Diane Descamps, E. Delaporte, Eric Caumes, François Clavel, Koenig, Ellen, Laurence Gerard, Maria-Bernarda Requena, Matthew Falagas

387

Publications

11.8K

Citations

H-Index

159

Concepts

All Affiliations

Sorbonne Université Inserm Hôpital Saint-Antoine Assistance Publique – Hôpitaux de Paris Université Paris Cité

About

Pierre‐Marie Girard is an author at Sorbonne Université specializing in medicine, hiv, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	33	59	3.8K
2	Public Health	15	15	901
3	Health Sciences	3	3	74
4	Natural Sciences	3	3	272
5	Engineering	1	1	158

Pierre‐Marie Girard

182

Publications

10.7K

Citations

H-Index

Page 1

	Year	Citations
Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection Chloe Orkin, Keikawus Arastéh, Miguel Górgolas Hernández-Mora, New England Journal of Medicine	2020	427
Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials Pedro Cahn, Juan Sierra Madero, José Ramón Arribas, The Lancet Hiv/aids CounsellingTreatment And PreventionWeek 48Clinical EpidemiologyClinical Trials	2018	371
Fanconi syndrome and renal failure induced by tenofovir: A first case report David Verhelst, Matthieu Monge, Jean‐Luc Meynard, American Journal of Kidney Diseases Renal FailureUrologyFanconi SyndromeFirst Case Report	2002	354
Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies Josep M. Llibre, Chien‐Ching Hung, Cynthia Brinson, The Lancet Treatment And PreventionHuman RetrovirusAntiviral TherapyNon-inferiority Sword-1Virological Suppression	2018	338
High Rate of Acquisition but Short Duration of Carriage of Multidrug-Resistant Enterobacteriaceae After Travel to the Tropics Étienne Ruppé, Laurence Armand-Lefèvre, Candice Estellat, Clinical Infectious Diseases	2015	263
Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial Jean‐Luc Meynard, Muriel Vray, Laurence Morand‐Joubert, AIDS	2002	244
Interactions between Atazanavir-Ritonavir and Tenofovir in Heavily Pretreated Human Immunodeficiency Virus-Infected Patients Anne‐Marie Taburet, Christophe Piketty, Corine Chazallon, Antimicrobial Agents and Chemotherapy Antiviral CompoundHuman RetrovirusImmunologyPharmacologyResistance Mutation (Virology)	2004	211
<i>Campylobacter</i> Bacteremia: Clinical Features and Factors Associated with Fatal Outcome Jérôme Pacanowski, V. Lalande, Karine Lacombe, Clinical Infectious Diseases	2008	201
Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment–Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials Pedro Cahn, Juan Sierra Madero, José Ramón Arribas, JAIDS Journal of Acquired Immune Deficiency Syndromes	2019	201
Combination Therapy With Telaprevir for Chronic Hepatitis C Virus Genotype 1 Infection in Patients With HIV Mark Sulkowski, Kenneth E. Sherman, Douglas T. Dieterich, Annals of Internal Medicine	2013	199

Page 1